Pain Management with Morphine

Initial Dosing

• For opioid-naïve adult patients with pain, the National Comprehensive Cancer Network recommends a starting dose of 5-15 mg of oral short-acting morphine sulfate every 4 hours as needed 1
• For severe pain requiring urgent relief, 2-5 mg intravenous morphine is recommended for opioid-naïve patients, with an equivalent parenteral dose being one-third of the oral dose (3:1 oral-to-parenteral conversion) 1

Dose Titration and Administration

• The European Society for Medical Oncology recommends starting with 1.5 mg IV bolus every 10 minutes until pain relief for IV titration, and allowing for rescue doses (up to hourly) for breakthrough pain 2
• Immediate-release formulations are preferred for initial titration, and can be administered as tablets or oral solution, with the goal of achieving good pain control within a short time period 1

• Standard conversion ratios include:

  Opioid	Conversion Ratio
  Oral morphine to IV morphine	1:3
  Oral morphine to subcutaneous morphine	1:3
  Oral morphine to transdermal fentanyl	100:1
  Oral morphine to oral hydromorphone	5:1 to 7.5:1
  Oral morphine to oral oxycodone	1.5:1
  Oral morphine to transdermal buprenorphine	75:1
  Oral morphine to oral methadone	Variable ratio (1:5 to 1:12)

Special Populations

• The National Comprehensive Cancer Network recommends using morphine with caution in patients with renal impairment due to potential accumulation of morphine-6-glucuronide (an active metabolite) 1
• Pediatric dosing requires weight-based calculations and is typically more conservative, with a moderate strength of evidence 4
• Consider using the lower end of the dosing range and reducing calculated doses by 25-50% for elderly patients or those with renal/hepatic impairment, with a moderate strength of evidence 3, 4

Monitoring and Adjustment

• The European Society for Medical Oncology recommends assessing pain control after 24 hours, adjusting the regular dose based on the total amount of rescue medication required, and continuing to monitor for efficacy and adverse effects 2
• Opioids should be used with caution and at reduced doses in patients with renal dysfunction, as recommended by the National Comprehensive Cancer Network (NCCN) with a moderate strength of evidence 5

• Monitoring parameters and frequencies include:

  Parameter	Frequency
  Vital signs	Every 15 minutes for the first hour, then hourly for 4 hours, then every 4 hours
  Pain scores	Every 30-60 minutes until stable, then every 4 hours
  Sedation level	Using a standardized scale, with the same frequency as vital signs
  Respiratory rate	Must be ≥8/min to continue PCA

Continuous Infusion and Patient Care

• For continuous infusion of morphine, dilute 2-5 mg of morphine in 50-100 ml of D5W or PNSS, with examples including:

  Concentration	Volume
  0.04 mg/ml	2 mg in 50 ml
  0.05 mg/ml	5 mg in 100 ml

• Calculate the hourly rate based on the total daily dose and adjust the infusion pump accordingly, with a moderate strength of evidence 4
• A prophylactic bowel regimen, including a stimulant laxative with or without a stool softener, is recommended to prevent constipation, as recommended by the NCCN with a moderate strength of evidence 3
• Prophylactic laxative regimen is almost always required to prevent constipation, and patient education on proper PCA use is essential, with a moderate strength of evidence 6

Buprenorphine and Breakthrough Pain

• Traditional approaches recommend waiting until the patient is in mild withdrawal before initiating buprenorphine, with a moderate strength of evidence 7
• Provide short-acting non-opioid analgesics for breakthrough pain during the first 24-72 hours, with a moderate strength of evidence 7
• Avoid using full opioid agonists for breakthrough pain if possible, as buprenorphine's high receptor affinity may block their effects, with a moderate strength of evidence 7

• The NCCN conversion table for transdermal buprenorphine indicates the following equivalencies:

  Patch Strength	Oral Morphine Equivalent	Oral Hydromorphone Equivalent
  25 mcg/h	60mg	7.5mg
  50 mcg/h	120mg	15mg
  75 mcg/h	180mg	22.5mg
  100 mcg/h	240mg	30mg